Neoadjuvant Pembrolizumab

DRUG3 trials

Sponsors

University of Texas Southwestern Medical Center, UNC Lineberger Comprehensive Cancer Center, Vall d'Hebron Institute of Oncology

Conditions

Breast CancerHER2-Negative Breast CarcinomaNode-positive Breast CancerRenal Cell CarcinomaTriple Negative Breast Cancer (TNBC)

Phase 2

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

RecruitingNCT05319015

University of Texas Southwestern Medical CenterRenal Cell Carcinoma

Start: 2023-01-06End: 2026-12-01Target: 30Updated: 2026-09-16

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

RecruitingNCT07276880

UNC Lineberger Comprehensive Cancer CenterBreast Cancer, HER2-Negative Breast Carcinoma, Node-positive Breast Cancer +1

Start: 2026-03-17End: 2032-01-01Target: 32Updated: 2026-04-27

Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

Not yet recruitingNCT07593040

Vall d'Hebron Institute of OncologyRenal Cell Carcinoma

Start: 2026-06-01End: 2031-06-01Target: 150Updated: 2026-05-20